Pages that link to "MTOR inhibitors"
Showing 34 items.
- Epilepsy (links | edit)
- Novartis (links | edit)
- Life extension (links | edit)
- Progeria (links | edit)
- Uterine cancer (links | edit)
- Sirolimus (links | edit)
- MTOR (links | edit)
- Phakomatosis (links | edit)
- DDIT4 (links | edit)
- MTOR inhibitor (redirect page) (links | edit)
- Chemotherapy (links | edit)
- Breast cancer (links | edit)
- Ovarian cancer (links | edit)
- Sirolimus (links | edit)
- Everolimus (links | edit)
- Imatinib (links | edit)
- Trastuzumab (links | edit)
- ATC code L (links | edit)
- ATC code L01 (links | edit)
- Gefitinib (links | edit)
- Rituximab (links | edit)
- Bevacizumab (links | edit)
- Cetuximab (links | edit)
- Erlotinib (links | edit)
- Ibritumomab tiuxetan (links | edit)
- Alemtuzumab (links | edit)
- Gemtuzumab ozogamicin (links | edit)
- Targeted therapy (links | edit)
- Sorafenib (links | edit)
- Sunitinib (links | edit)
- Lapatinib (links | edit)
- Nilotinib (links | edit)
- Dasatinib (links | edit)
- Denileukin diftitox (links | edit)
- Tositumomab (links | edit)
- Monoclonal antibody therapy (links | edit)
- Panitumumab (links | edit)
- Vandetanib (links | edit)
- Edrecolomab (links | edit)
- Pertuzumab (links | edit)
- Catumaxomab (links | edit)
- Ipilimumab (links | edit)
- Tremelimumab (links | edit)
- Inotuzumab ozogamicin (links | edit)
- Ofatumumab (links | edit)
- Semaxanib (links | edit)
- Protein kinase inhibitor (links | edit)
- Cediranib (links | edit)
- Pazopanib (links | edit)
- Temsirolimus (links | edit)
- Axitinib (links | edit)
- ARID1A (links | edit)
- Ridaforolimus (links | edit)
- Lestaurtinib (links | edit)
- Bosutinib (links | edit)
- Aflibercept (links | edit)
- Elotuzumab (links | edit)
- Blinatumomab (links | edit)
- Afatinib (links | edit)
- Ramucirumab (links | edit)
- Obinutuzumab (links | edit)
- Neratinib (links | edit)
- ARIAD Pharmaceuticals (links | edit)
- Necitumumab (links | edit)
- Oportuzumab monatox (links | edit)
- Toceranib (links | edit)
- Lenvatinib (links | edit)
- Regorafenib (links | edit)
- Apatinib (links | edit)
- Brentuximab vedotin (links | edit)
- PI3K/AKT/mTOR pathway (links | edit)
- CDK inhibitor (links | edit)
- Olaratumab (links | edit)
- Mubritinib (links | edit)
- Erbulozole (links | edit)
- Tyrosine kinase inhibitor (links | edit)
- Crizotinib (links | edit)
- Tivozanib (links | edit)
- Vemurafenib (links | edit)
- Quizartinib (links | edit)
- Trastuzumab emtansine (links | edit)
- Midostaurin (links | edit)
- Germinal center B-cell like diffuse large B-cell lymphoma (links | edit)
- Ruxolitinib (links | edit)
- Nintedanib (links | edit)
- Cabozantinib (links | edit)
- Ponatinib (links | edit)
- Vismodegib (links | edit)
- Selumetinib (links | edit)
- Brigatinib (links | edit)
- Chemotherapy-induced nausea and vomiting (links | edit)
- Mogamulizumab (links | edit)
- Moxetumomab pasudotox (links | edit)
- Daratumumab (links | edit)
- Prohibitin-targeting peptide 1 (links | edit)
- Fedratinib (links | edit)
- Momelotinib (links | edit)
- Ibrutinib (links | edit)
- Nivolumab (links | edit)
- Masitinib (links | edit)
- Trametinib (links | edit)
- Dabrafenib (links | edit)
- Margetuximab (links | edit)
- Encorafenib (links | edit)
- Pembrolizumab (links | edit)
- Palbociclib (links | edit)
- Cobimetinib (links | edit)
- Pacritinib (links | edit)
- Radotinib (links | edit)
- Icotinib (links | edit)
- Zolbetuximab (links | edit)
- Sonidegib (links | edit)
- Dacomitinib (links | edit)
- Ceritinib (links | edit)
- Filgotinib (links | edit)
- Dinutuximab (links | edit)
- Binimetinib (links | edit)
- Enfortumab vedotin (links | edit)
- Polatuzumab vedotin (links | edit)
- Durvalumab (links | edit)
- Isatuximab (links | edit)
- Atezolizumab (links | edit)
- Sacituzumab govitecan (links | edit)
- Osimertinib (links | edit)
- List of antineoplastic agents (links | edit)
- Avelumab (links | edit)
- Venetoclax (links | edit)
- Acalabrutinib (links | edit)
- Alectinib (links | edit)
- Pexidartinib (links | edit)
- Mirvetuximab soravtansine (links | edit)
- Rociletinib (links | edit)
- Entrectinib (links | edit)
- Bermekimab (links | edit)
- Capmatinib (links | edit)
- Tesevatinib (links | edit)
- Tislelizumab (links | edit)
- Olmutinib (links | edit)
- Lorlatinib (links | edit)
- Glasdegib (links | edit)
- Larotrectinib (links | edit)
- Tucatinib (links | edit)
- Erdafitinib (links | edit)
- Sitravatinib (links | edit)
- Silmitasertib (links | edit)
- Gilteritinib (links | edit)
- Loncastuximab tesirine (links | edit)
- Cemiplimab (links | edit)
- Ivosidenib (links | edit)
- Tepotinib (links | edit)
- Dostarlimab (links | edit)
- David Fajgenbaum (links | edit)
- Zanubrutinib (links | edit)
- Sotorasib (links | edit)
- Abrocitinib (links | edit)
- Trastuzumab deruxtecan (links | edit)
- Avapritinib (links | edit)
- Pemigatinib (links | edit)
- Selpercatinib (links | edit)
- Ripretinib (links | edit)
- Pertuzumab/trastuzumab/hyaluronidase (links | edit)
- Tafasitamab (links | edit)
- Belantamab mafodotin (links | edit)
- Trastuzumab/hyaluronidase (links | edit)
- Pralsetinib (links | edit)
- Naxitamab (links | edit)
- Mobocertinib (links | edit)
- Adagrasib (links | edit)
- Amivantamab (links | edit)
- Infigratinib (links | edit)
- Tisotumab vedotin (links | edit)
- Asciminib (links | edit)
- Tebentafusp (links | edit)
- Nivolumab/relatlimab (links | edit)
- Mosunetuzumab (links | edit)
- Teclistamab (links | edit)
- Futibatinib (links | edit)
- Pirtobrutinib (links | edit)
- Talquetamab (links | edit)
- Inavolisib (links | edit)
- Retifanlimab (links | edit)
- Glofitamab (links | edit)
- Epcoritamab (links | edit)
- Elranatamab (links | edit)
- Toripalimab (links | edit)
- Fruquintinib (links | edit)
- Capivasertib (links | edit)
- Repotrectinib (links | edit)
- Odronextamab (links | edit)
- Tarlatamab (links | edit)
- Parsaclisib (links | edit)
- Aumolertinib (links | edit)
- Surufatinib (links | edit)
- Orelabrutinib (links | edit)
- Tovorafenib (links | edit)
- Sugemalimab (links | edit)
- Axatilimab (links | edit)
- Lazertinib (links | edit)
- Atezolizumab/hyaluronidase (links | edit)
- Serplulimab (links | edit)
- Revumenib (links | edit)
- Zanidatamab (links | edit)
- User:Mikael Häggström/Article creations (links | edit)
- User:Fvasconcellos/T-DM1 (links | edit)
- User:Y-S.Ko/Wikipedia course/Medical/Oncology (links | edit)
- User:Y-S.Ko/Wikipedia course/Pharmacology/L-V (links | edit)
- User:Noxoug1/Tovorafenib (links | edit)
- User:Noxoug1/template-product (links | edit)
- User:Noxoug1/Lazertinib-template (links | edit)
- Template:Targeted cancer therapeutic agents (links | edit)
- Rapalog (redirect to section "Rapamycin and rapalogs") (links | edit)
- Senolytic (links | edit)
- Discovery and development of mTOR inhibitors (redirect page) (links | edit)
- Immunosuppression (links | edit)
- Immunosuppressive drug (links | edit)
- NMDA receptor (links | edit)
- PTEN (links | edit)
- Drug discovery (links | edit)
- Drug design (links | edit)
- Preclinical development (links | edit)
- Protein kinase B (links | edit)
- Drug development (links | edit)
- Hit to lead (links | edit)
- Temsirolimus (links | edit)
- Discovery and development of statins (links | edit)
- Discovery and development of ACE inhibitors (links | edit)
- Ridaforolimus (links | edit)
- Discovery and development of cyclooxygenase 2 inhibitors (links | edit)
- Discovery and development of angiotensin receptor blockers (links | edit)
- Discovery and development of triptans (links | edit)
- Discovery and development of dipeptidyl peptidase-4 inhibitors (links | edit)
- Discovery and development of non-nucleoside reverse-transcriptase inhibitors (links | edit)
- Discovery and development of HIV-protease inhibitors (links | edit)
- Discovery and development of TRPV1 antagonists (links | edit)
- Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors (links | edit)
- Melatonin receptor agonist (links | edit)
- Discovery and development of proton pump inhibitors (links | edit)
- Discovery and development of antiandrogens (links | edit)
- Discovery and development of cephalosporins (links | edit)
- Discovery and development of integrase inhibitors (links | edit)
- C-Met inhibitor (links | edit)
- Phases of clinical research (links | edit)
- 5-HT2C receptor agonist (links | edit)
- Discovery and development of direct thrombin inhibitors (links | edit)
- MTOR inhibitors (links | edit)
- Discovery and development of phosphodiesterase 5 inhibitors (links | edit)
- Discovery and development of beta-blockers (links | edit)
- GABAA receptor positive allosteric modulator (links | edit)
- Cereblon E3 ligase modulator (links | edit)
- Development and discovery of SSRI drugs (links | edit)
- Discovery and development of gliflozins (links | edit)
- Discovery and development of neuraminidase inhibitors (links | edit)
- Discovery and development of beta2 agonists (links | edit)
- Discovery and development of gastrointestinal lipase inhibitors (links | edit)
- Discovery and development of direct Xa inhibitors (links | edit)
- Discovery and development of NS5A inhibitors (links | edit)
- Discovery and development of 5α-reductase inhibitors (links | edit)
- Talk:MTOR inhibitors (links | edit)
- Talk:Discovery and development of mTOR inhibitors (transclusion) (links | edit)
- User:HlynurT/Discovery and development of thalidomide and its analogs (links | edit)
- User:Hopur2bdk/Direct thrombin inhibitors, drug discovery and development (links | edit)
- User:Lybbar12/Drug discovery and development of mTOR inhibitors (links | edit)
- User:Jimw338/Books/Barrett's Esophogus (links | edit)
- User:Haysammercal/Books/nephrology (links | edit)
- User:Mogsan1/sandbox (links | edit)
- User:Goorgle/Books/Pharmacology Wiki 101 (links | edit)
- User:Goorgle/Books/Cancer Wiki 101 (links | edit)
- User talk:PFHLai/Archive 12 (links | edit)
- User talk:Lybbar12 (links | edit)
- Wikipedia:Recent additions/2012/October (links | edit)
- Wikipedia:WikiProject Medicine/Lists of pages/Low-importance medicine articles (links | edit)
- Wikipedia:WikiProject Pharmacology/Lists of pages/Pharmacology all pages (links | edit)
- Wikipedia:WikiProject Medicine/Popular pages En 2013b (links | edit)
- Wikipedia:WikiProject Pharmacology/Drugbox and WP:PHARM crosscheck (links | edit)
- Template:Drug design (links | edit)
- Template:Did you know nominations/Discovery and development of mTOR inhibitors (links | edit)
- Buparlisib (links | edit)
- Sapanisertib (links | edit)
- Facial infiltrating lipomatosis (links | edit)
- Cardiac allograft vasculopathy (links | edit)
- Duojia Pan (links | edit)
- Mtori (links | edit)
- 2022 in science (links | edit)
- Timeline of aging research (links | edit)
- Endocrine therapy resistance in breast cancer (links | edit)
- Talk:Β-Hydroxy β-methylbutyric acid (links | edit)
- Talk:MTOR inhibitors (transclusion) (links | edit)
- User:Wouterstomp/test (links | edit)
- User:Bioewiki/sandbox (links | edit)
- User:PriceDL/List of all WikiProject Medicine articles (links | edit)
- User:CFCF/sandbox/46 (links | edit)
- User talk:217.118.78.98 (links | edit)
- Wikipedia:WikiProject Medicine/Recognized content (links | edit)
- Wikipedia:WikiProject Medicine/Lists of pages/Articles (links | edit)
- Wikipedia:WikiProject Pharmacology/Lists of pages/Pharmacology articles (links | edit)
- Wikipedia:Typo Team/moss/M (links | edit)
- Draft:List of proteins in the human body (links | edit)